154 results about "Molecular imaging" patented technology

The invention belongs to the technical field of biological medicine and electronic information technology, and discloses an atherosclerosis model based on nano-molecule magnetic resonance imaging and a machine learning algorithm, a nano-targeting probe and application of the atherosclerosis model based on the nano-molecule magnetic resonance imaging and the machine learning algorithm. A high-resolution MRI image capable of specifically displaying foam macrophage distribution in the plaque is obtained; then, image omics features are extracted from the images, a machine learning model which is constructed based on the features and verified by pathological labels is adopted for analysis, and finally an objective and quantitative plaque vulnerability score is output. According to the model disclosed by the invention, an objective and quantitative risk score can be output by fusing nano-targeted molecular imaging and machine learning, and accurate and reliable quantification of plaque vulnerability is realized. According to the invention, through systematic integration of targeted molecular imaging and machine learning, significant technical progress is brought.

A detector system for molecular imaging of a radionuclide comprises a 3D semiconductor detector comprising a plurality of sensor stacks of sensors made of a semiconductor material having an average atomic number Z below 40. A read-out circuitry connected to the pixels is configured to output, for each interaction induced by an incident gamma ray in the detector, a signal representative of a time, a position and an energy of the interaction in the detector. The interactions in the detector belonging to a same event induced by the incident gamma ray are predicted based on the output signals and used to estimate a direction of the incident gamma ray and reconstruct an image based on the estimated directions of incident gamma rays.

The invention relates to an oxidase response type molecular probe as well as a preparation method and application thereof, and belongs to the technical field of medical imaging. Aiming at the problem that the inflammation activity is difficult to accurately evaluate in the prior art, the invention provides a molecular imaging probe capable of responding to the activity of in-vivo myeloperoxidase (MPO), and the molecular imaging probe can be used for real-time and non-invasive imaging monitoring of the activity of the in-vivo MPO, so that the activity of the inflammatory reaction of a focus is accurately evaluated. The invention provides a chelating agent with structural characteristics of a chelating unit and an enzyme response unit, and is characterized in that the enzyme response molecular probe is constructed by taking rigid framework cyclohexanediamine (CDTA) as a transition metal chelating unit and taking electron-rich functional groups (such as phenol, catechol or 5-hydroxytryptamine) as the enzyme response unit. The probe is chelated with paramagnetic metal (such as Mn < 2 + >) for magnetic resonance imaging (MRI) or radioactive metal (such as 68Ga) for positron emission tomography (PET), so that specific response to MPO activity is realized. The dynamic stability of the probe is remarkably improved; after the MPO is responded, the relaxation efficiency is improved by 2-3 times, and the sensitivity is optimized; the cytotoxicity is low; in an acute pancreatitis model, the MRI contrast noise ratio (delta CNR) reaches 77.39 + / -7.04 and is 4.2 times that of a control group, the PET uptake rate is remarkably improved, bimodal imaging is supported, and accurate positioning and quantitative evaluation of the inflammation activity are achieved.

The invention discloses a living blood vessel and lymph multi-parameter quantitative photoacoustic microscopic imaging system which comprises a high repetition frequency laser source, a photoacoustic scanning probe and a molecular imaging device. Through the cooperation of the multi-wavelength fast switching laser and the high-speed scanning probe, synchronous, dynamic and quantitative imaging of vascular function parameters and lymph concentration in a living tissue microenvironment is realized. The system has a video-level imaging rate and can capture a rapid biological process; through coaxial design of dispersion correction and a photoacoustic focus, high spatial resolution and high signal-to-noise ratio of a multispectral image are guaranteed; and the compact probe design realizes large-range scanning. The technology provides a powerful in-vivo visualization tool for research on life science problems such as tumor evolution and drug metabolism.

The invention is suitable for the technical field of biological medicine and nuclear medicine, and provides a PD-L1 targeting compound, a radioactive tracer agent and a preparation method and application of the PD-L1 targeting compound and the radioactive tracer agent. The radioactive tracer provided by the invention has strong binding force with PD-L1, can accurately locate PD-L1 in vivo, has excellent in-vivo targeting performance, and can achieve the purpose of tumor molecular imaging through nuclear medicine imaging; meanwhile, noninvasive visualization of PD-L1 expression is achieved, non-invasive tumor diagnosis can be effectively completed through small animal PET / CT verification, and the clinical application prospect is wide; in addition, the PD-L1 targeting compound and the radioactive tracer derived from the PD-L1 targeting compound further have the advantages of being simple in preparation process, low in cost, high in specificity, good in in-vivo and in-vitro stability, long in imaging period, easy to clinically convert and the like, and the comprehensive performance is outstanding.

The invention relates to the technical field of optical molecular imaging, in particular to a fluorescent molecular tomography three-dimensional reconstruction system, method and device based on pixel and region integration layering Mama (PR3SM) and a three-dimensional scanning (Tri-scan) mechanism. Aiming at the problems of how to effectively capture global and local spatial characteristics of a fluorescence signal, how to accurately model a radial aggregation and diffusion mode of a fluorescence probe and how to realize a self-adaptive loss function to improve the reconstruction precision, the invention provides a layered three-way scanning Mama fluorescence molecular tomography reconstruction system based on pixel-region integration. The reconstruction precision is improved by introducing a Mama model, the feature modeling capability is enhanced by combining a layered PR-Mama module with a pixel-level SSM and a region-level SSM, forward, backward and spiral center scanning modes are fused through a three-way scanning mechanism, and a fluorophore distribution mode is effectively captured; the adaptive structure senses the loss function, integrates the mean square error and the local structure similarity loss, and improves the adaptability of the loss function.

The invention belongs to the technical field of radiopharmaceuticals, and particularly relates to a GPC3 targeted polypeptide probe and application thereof. According to the polypeptide probe targeting GPC3, non-natural functional groups are introduced to modify polypeptide ligands so as to enhance affinity, radiolabeling is carried out, and the polypeptide probe is used for PET molecular imaging diagnosis. The polypeptide probe shows good tumor targeting in vivo, the uptake of tumor tissues is remarkably different from that of normal liver tissues, the background of the normal liver tissues is clear, and a powerful tool and a theoretical basis are provided for noninvasive precise diagnosis of GPC3 positive liver cancer.

The invention belongs to the technical field of targeting peptides, and particularly relates to an EGFR targeting peptide, a fluorescent probe, a composition and application. The targeting peptide has an amino acid sequence as shown in SEQ ID NO: 1. Through verification, the targeting peptide has the capability of selective enrichment in tumor cells, and is beneficial to tumor recognition and treatment. The fluorescent probe coupled by the targeting peptide and the ICG fluorescent dye can specifically recognize and target an EGFR receptor, realizes effective aggregation and retention at a tumor part, is suitable for targeted diagnosis and treatment of tumors, can realize accurate imaging, has important clinical transformation potential, and becomes a molecular imaging probe with application prospects.

The 18F-labeling of unprotected peptides and sugars via thioarylation using a Au(III)-[˜F]fluoroaryl complex is reported. The chemoselective method generates 18F-labeled S-aryl bioconjugates in an aqueous environment in 15 min with high radiochemical yields and displays excellent functional group tolerance. This approach utilizes an air and moisture stable, robust organometallic Au(III) complex and highlights the versatility of designer organometallic reagents as efficient agents for rapid radiolabeling.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The invention provides a molecular probe targeting EDB-FN as well as a preparation method and application of the molecular probe. The structural formula of the molecular probe targeting EDB-FN is shown in the specification, according to the molecular probe targeting EDB-FN, the probe is based on a cyclic peptide probe with Lys-Glu side chain lactam bridge conformation fixed, the connection mode of a DOTA chelating agent is optimized, and the clinical transformation bottlenecks that an existing probe is poor in stability, low in affinity, insufficient in targeting specificity, poor in diagnosis and treatment integration compatibility and the like are solved. The probe can be used for early diagnosis and molecular imaging research of tumors, and provides a reliable basis for tumor malignancy degree evaluation and treatment effect monitoring.

The application relates to the technical field of electronic science and technology, and provides a driving collection controller of a molecular imaging system, which comprises an MCU, a first DAC circuit, a second DAC circuit and a signal conditioning circuit; the MCU converts a first driving signal into a second driving signal through the first DAC circuit to control a first driver; the MCU converts the first driving signal into a third driving signal through the second DAC circuit to control a second driver; and the MCU receives an input signal of an APD or sends a control signal to the APD through the signal conditioning circuit. The first driving signal output by the MCU is converted into the second driving signal and the third driving signal which can be used by different drivers through the first DAC circuit and the second DAC circuit, so that different instruments of the molecular imaging system can be integrated in the driving collection controller for control, the operation is convenient, and the application has good application value.

The present invention provides a method for preparing and using a CD70-specific diagnostic-integrated molecular imaging probe, which comprises a tumor targeting group and a radionuclide, the tumor targeting group being selected from a CD70-specific nanobody or a CD70-specific nanobody fusion protein, the CD70-specific nanobody being B3 or B6 having the amino acid sequences set forth in SEQ ID NO. 1 and SEQ ID NO. 3, and the CD70-specific nanobody fusion protein being ABDB3 or ABDB6 having the amino acid sequences set forth in SEQ ID NO. 5 and SEQ ID NO. 7. The present invention achieves noninvasive visualization of human CD70 molecule expression and realizes noninvasive diagnosis of renal cell carcinoma. This probe has the advantages of simple preparation, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical translation.

The application discloses a polypeptide for targeted recognition of a neuroendocrine tumor marker INSM1 and products and applications thereof, and belongs to the fields of molecular imaging and protein polypeptide drug engineering. Specifically, the application relates to development of a polypeptide with high affinity and specificity to a neuroendocrine tumor marker insulinoma-associated protein 1 (INSM1). The application discloses an amino acid sequence of the polypeptide and related applications. The polypeptide is used for labeling and preparation of a polypeptide probe, can be specifically combined with the INSM1 protein, and can be used for in-vivo and in-vitro imaging of neuroendocrine tumors, so as to overcome a diagnosis difficulty caused by a hidden onset of the neuroendocrine tumor and realize early positioning and qualitative diagnosis.

The invention discloses an application of a tumor-associated macrophage targeting nanoprobe in ultrasensitive magnetic resonance molecular imaging of in-vivo in-situ lung cancer. The tumor-associated macrophage targeting nanoprobe prepared by the method provided by the invention is loaded with water-insoluble supramolecular celopphane, so that Xe'molecular cage 'celopphane can be uniformly dispersed in water and a biological system, and is used for in-vivo hyperpolarized 129Xe magnetic resonance imaging. According to the nanoprobe, mannose modification is carried out on the surface of the nanoprobe, so that the nanoprobe can effectively target tumor-related macrophages in a tumor area, and targeted detection of in-situ lung cancer tumors is realized; the surface of the nanoprobe is subjected to near-infrared fluorescence molecular modification, so that fluorescence / magnetic resonance bimodal detection of solid tumors can be realized. In combination with the advantage that local drug concentration can be improved by pulmonary drug delivery, a strong 129Xe magnetic resonance signal of the developed probe can be directly detected in vivo, and in-vivo 129Xe magnetic resonance molecular imaging is realized on an in-situ lung cancer model mouse through a direct sampling imaging mode.

The present invention pertains to the field of protein engineering, molecular imaging, molecular diagnostics, and biopharmaceutics. Provided herein are six unique Proteimer protein scaffolds (TEX-S2 / S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2) that demonstrate specificity and affinity comparable to antibodies across a broad range of therapeutic targets. Methods and protocols are provided for generating non-native protein aptamers, Proteimers, which are capable of binding to a diverse set of targets, including RNA, DNA, proteins, post-translational modifications, peptides, small molecules, and prosthetic groups. This platform supports the creation of biotherapeutic aptamers from Proteimer scaffolds for the treatment of various diseases.

The invention discloses a cationic peptide compound for targeting cartilage as well as a preparation method and application of the cationic peptide compound. The cationic peptide compound has a structural general formula as shown in the specification: R-(Xa-Nlys-Yb) n, wherein R is H, a drug active molecule or a group containing a signal marker, and X and Y are independently selected from any one of glycine residues and imidic acid residues; nlys is a residue of N-(4-aminobutyl) glycine; a and b are independently selected from any integer between 0 and 3; n is any positive integer from 3 to 10. The compound can target a glycosaminoglycan chain in cartilage through electrostatic interaction, has an effect of resisting protease degradation, and is beneficial to prolonging the in-vivo circulation time. The compound supports systemic administration, can be used for marking whole body cartilage through intravenous injection, is used for monitoring cartilage development, aging and pathological changes in real time, and has wide application potential in the aspects of molecular imaging, drug delivery and biological materials for treating cartilage-related diseases.

The application belongs to the technical field of biological medicine and nanomaterials, and particularly relates to a method for enhancing multi-nuclear magnetic resonance signals based on lipid nanoparticle loaded with hole banana. 129 Xe molecular imaging and related biomedical applications provide a new technical path.

The invention provides an LAG-3 targeted diagnosis and treatment integrated molecular imaging probe as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) carrying out ultrafiltration on an anti-human LAG-3 monoclonal antibody by using a buffer solution; adding a bifunctional chelating agent for reaction, and performing ultrafiltration purification to obtain a labeled precursor DOTA-alphaLAG-3; (2) mixing the labeled precursor DOTA-alphaLAG-3 with a buffer solution, and then adding radionuclide for reaction; and after the reaction is finished, carrying out ultrafiltration purification on the obtained reaction liquid to obtain the LAG-3 targeted diagnosis and treatment integrated molecular imaging probe. The obtained LAG-3 targeted diagnosis and treatment integrated molecular imaging probe can play a synergistic anti-tumor effect with immunotherapy.

The present invention discloses a magnetic resonance molecular imaging method and system for dynamically reading the accumulation of CEST signals. The method includes: applying N CEST saturation pulses for an object to be detected within each repetition time by a magnetic resonance imaging device; after each of the first N-1 CEST saturation pulses, a low-resolution, small-angle reading method is used to read the signal to obtain N-1 first-class signals; after the Nth CEST saturation pulse, a high-resolution, large-angle reading method is used to read the signal to obtain a second-class signal to compensate for the first-class signal, and N saturation-weighted magnetic resonance images of the object to be detected are obtained based on the compensated first and second-class signals. The method can improve the signal-to-noise ratio and robustness of CEST imaging, and can dynamically change according to the N readout signals, with better quantitativeness, such as reducing the influence of tissue longitudinal relaxation (T1) to obtain a proton exchange rate image.

A detector system (1) for molecular imaging of a radionuclide comprises a 3D semiconductor detector (100) comprising a plurality of sensor stacks (110) of sensors (120) made of a semiconductor material having an average atomic number Z below 40 A read-out circuitry (!26) connected to the pixels (125) is configured to output, for each interaction induced by an incident gamma ray in the detector (100), a signal representative of a time, a position and an energy of the interaction in the detector (100). The interactions in the detector (100) belonging to a same event induced by the incident gamma ray are predicted based on the output signals and used to estimate a direction of the incident gamma ray and reconstruct an image based on the estimated directions of incident gamma rays.

A programmed cell death ligand 1 (PD-L1) targeting polypeptide, a molecular imaging probe, and a use thereof are provided. The PD-L1 targeting polypeptide includes any one of the following polypeptides: (1) a polypeptide shown in at least one of SEQ ID NO: 1 to SEQ ID NO: 9; and (2) a polypeptide that is derived from an amino acid sequence of (1) through a substitution and / or a deletion and / or an addition of one or more amino acid residues and has the same function as the amino acid sequence. The magnetic resonance molecular imaging probe based on the PD-L1 targeting polypeptide enables the early diagnosis and evaluation of a tumor and an immune-mediated myocardial injury.

Disclosed in the present invention are a simple phenolic acid derivative- and rosmarinic acid derivative-based multimodal imaging probe and a use thereof. The multimodal imaging probe of the present invention has a structure selected from those represented by formulas (I to III). By subjecting phenolic acids such as danshensu, caffeic acid, ferulic acid, and rosmarinic acid to derivatization modification and by means of molecular imaging technology, the present invention realizes in vivo tracing and imaging of diseases such as various tumors (liver cancer, pancreatic cancer, and breast cancer), stroke, myocardial infarction, and acute kidney injury, and achieves in vivo and in vitro high-contrast imaging, real-time monitoring, and qualitative and quantitative evaluation. Moreover, the probe of the present invention itself has good metabolic properties and targeting performance, is simple to prepare and low in cost, and has broad clinical application prospects.

Described herein are methods for imaging magnetic resonance imaging (MRI) agents containing nanoconstructs therein using diffusion weighted fast spin echo (FSE) or gradient and spin echo (GRASE) methods.

The application belongs to the technical field of molecular imaging and nanobody of tumor diagnosis and treatment, and discloses a Trop2 targeted nanobody fluorescent probe and a preparation method and application thereof. The nanobody T4 or ABDT4 capable of specifically recognizing TROP2 is connected with near-infrared two-region fluorescent dye through a chemical coupling mode to obtain a nanobody fluorescent probe with TROP2 targeting capability. The application realizes selective recognition at a molecular level by introducing the nanobody capable of specifically recognizing TROP2, which is helpful to improve the fluorescent contrast between tumors and normal tissues. Stable probe products are obtained through a controllable coupling and purification process, which is beneficial to repeated preparation and subsequent popularization and application.

The invention discloses a dual-response type near-infrared two-region quantum dot nanoprobe as well as preparation and application thereof, and belongs to the technical field of biomedical nanomaterials and molecular imaging. The quantum dot nanoprobe comprises an inner core and a shell, wherein the shell is coated outside the inner core; the inner core comprises a near-infrared emission quantum dot core, and the surface of an NIR-II quantum dot is connected with a response peptide and a quencher; the shell is prepared from a polylactic acid-glycolic acid copolymer, polylactic acid, polycaprolactone, a polylactide-polyethylene glycol copolymer, a polylactide-polycaprolactone copolymer, a polysulfide block copolymer and the like. According to the NIR-II quantum dot nanoprobe disclosed by the invention, a response peptide chain and a fluorescence quencher are introduced through chemical modification, and a signal off-on function is realized, so that an activated fluorescent probe with high specificity and high contrast is constructed; the nano-composite particle with controllable particle size, adjustable fluorescence and stable structure is formed, has targeting property, responsiveness and biocompatibility, and is suitable for accurate real-time imaging in a complex in-vivo environment.

1. The name of the design product: single photon emission and X-ray computed tomography system. 2. The use of the design product: functional and structural imaging, a nuclear medicine molecular imaging device integrating SPECT / CT multiple modalities three-dimensional medical image imaging and processing functions. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

The invention discloses a radionuclide-labeled isoindole-piperidinedione derivative and application thereof, and the structural formula of the radionuclide-labeled isoindole-piperidinedione derivative is shown in the specification. E3 ubiquitin ligase key protein CRBN is used as a new target for nuclear medicine molecular imaging research; dynamic expression of CRBN in a tumor microenvironment is accurately described by constructing a targeted molecular probe with an isoindole-piperidinedione parent nucleus structure, imaging guidance is provided for clinically and accurately screening benefited people and predicting the therapeutic effect of targeted CRBN, and imaging examples are also provided for researching dynamic expression of other key proteins in a ubiquitination system.

A detector system for molecular imaging of a radionuclide comprises a 3D semiconductor detector comprising a plurality of sensor stacks of sensors made of a semiconductor material having an average atomic number Z below 40. A read-out circuitry connected to the pixels is configured to output, for each interaction induced by an incident gamma ray in the detector, a signal representative of a time, a position and an energy of the interaction in the detector. The interactions in the detector belonging to a same event induced by the incident gamma ray are predicted based on the output signals and used to estimate a direction of the incident gamma ray and reconstruct an image based on the estimated directions of incident gamma rays.

The application discloses a kind of composite super-resolution ultrasonic molecular imaging method and related equipment, belong to ultrasonic imaging technical field, by obtaining high frame rate ultrasonic contrast image and conventional ultrasonic contrast image sequence, high frame rate ultrasonic contrast image sequence is carried out super-resolution image reconstruction, obtains super-resolution blood vessel image, ultrasonic molecular imaging processing is carried out to conventional ultrasonic contrast image sequence, obtains ultrasonic molecular imaging image, to super-resolution blood vessel image and ultrasonic molecular imaging image is carried out composite super-resolution imaging processing, obtains composite super-resolution ultrasonic molecular imaging result, to the selective display of composite super-resolution ultrasonic molecular imaging result is carried out, and composite super-resolution molecular imaging parameter extraction and analysis can be simultaneously super-resolution visualized vascular structure and blood flow in imaging area and specific biomolecule or marker distribution, simultaneously obtain vascular structure information and hemodynamics and specific target distribution function information.